NYSE:GKOS Glaukos (GKOS) Stock Price, News & Analysis $119.82 +2.17 (+1.84%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$117.45▼$120.1550-Day Range$107.49▼$125.7452-Week Range$59.22▼$126.96Volume613,359 shsAverage Volume593,885 shsMarket Capitalization$6.04 billionP/E RatioN/ADividend YieldN/APrice Target$120.64 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Glaukos alerts: Email Address Glaukos MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside0.7% Upside$120.64 Price TargetShort InterestHealthy4.80% of Shares Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews Sentiment0.80Based on 4 Articles This WeekInsider TradingSelling Shares$2.41 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.25) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.96 out of 5 starsMedical Sector237th out of 936 stocksSurgical & Medical Instruments Industry31st out of 101 stocks 2.4 Analyst's Opinion Consensus RatingGlaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageGlaukos has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Glaukos' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.80% of the outstanding shares of Glaukos have been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Glaukos has recently decreased by 5.84%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlaukos has received a 65.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical laser systems", "Medical technology engineering", and "Surgical instruments" products. See details.Environmental SustainabilityThe Environmental Impact score for Glaukos is -0.90. Previous Next 2.7 News and Social Media Coverage News SentimentGlaukos has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Glaukos this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for GKOS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,411,171.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Glaukos is held by insiders.Percentage Held by Institutions99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Glaukos' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($2.25) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -41.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -41.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 12.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Glaukos' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Glaukos Stock (NYSE:GKOS)Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Read More GKOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GKOS Stock News HeadlinesJuly 10, 2024 | insidertrades.comInsider Selling: Glaukos Co. (NYSE:GKOS) COO Sells 2,250 Shares of StockJuly 24 at 6:49 AM | americanbankingnews.comGlaukos (GKOS) Scheduled to Post Quarterly Earnings on WednesdayJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 18, 2024 | americanbankingnews.comGlaukos (NYSE:GKOS) Sets New 52-Week High on Analyst UpgradeJuly 16, 2024 | americanbankingnews.comGlaukos (NYSE:GKOS) Price Target Raised to $141.00July 16, 2024 | americanbankingnews.comGlaukos (NYSE:GKOS) Price Target Raised to $131.00 at BTIG ResearchJune 14, 2024 | businesswire.comGlaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common StockMay 30, 2024 | seekingalpha.comGlaukos Stock: Still Unproven Whether A New Bull Market Has BegunJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 28, 2024 | businesswire.comGlaukos Announces Participation in Upcoming Investor ConferencesMay 22, 2024 | markets.businessinsider.comDeep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)May 8, 2024 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$113May 6, 2024 | msn.comJefferies Upgrades Glaukos (GKOS)May 6, 2024 | msn.comGlaukos rises on upgrade to Buy at JefferiesMay 6, 2024 | markets.businessinsider.comBuy Rating on Glaukos with Strong Growth Prospects for iDose and MIGS Market ShareMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Glaukos on Strong Q1 Performance and Promising iDose ProspectsMay 2, 2024 | msn.comGlaukos Corporation (NYSE:GKOS) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comGlaukos Corp (GKOS) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ...See More Headlines Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/26/2024Next Earnings (Confirmed)7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:GKOS CUSIPN/A CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees907Year FoundedN/APrice Target and Rating Average Stock Price Target$120.64 High Stock Price Target$141.00 Low Stock Price Target$100.00 Potential Upside/Downside+1.6%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,660,000.00 Net Margins-43.15% Pretax Margin-42.88% Return on Equity-24.69% Return on Assets-12.27% Debt Debt-to-Equity Ratio0.78 Current Ratio5.38 Quick Ratio4.68 Sales & Book Value Annual Sales$314.71 million Price / Sales19.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book12.55Miscellaneous Outstanding Shares50,370,000Free Float47,144,000Market Cap$5.98 billion OptionableOptionable Beta1.06 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Thomas William Burns (Age 63)Chairman & CEO Comp: $774.9kMr. Joseph E. Gilliam (Age 48)President & COO Comp: $1.18MMr. Alex R. Thurman (Age 54)Senior VP & CFO Comp: $621.24kDr. Tomas Navratil Ph.D. (Age 47)Chief Development Officer Comp: $866.18kDr. Mory Gharib Ph.D.Co-FounderMr. Christopher William LewisVice President of Investor Relations & Corporate AffairsMs. Diana A. SchererVP of Compliance & Deputy General CounselMs. Michele M. AllegrettoSenior Vice President of Human ResourcesMr. Chris M. Calcaterra (Age 64)Executive Vice President of Global Commercial Operations Comp: $198.66kMs. Jane E. Rady (Age 76)Senior Vice President of Corporate Strategy & Business Development More ExecutivesKey CompetitorsWest Pharmaceutical ServicesNYSE:WSTBaxter InternationalNYSE:BAXInsuletNASDAQ:PODDTeleflexNYSE:TFXGlobus MedicalNYSE:GMEDView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 26,510 shares on 7/26/2024Ownership: 0.821%Allspring Global Investments Holdings LLCBought 246,322 shares on 7/26/2024Ownership: 0.819%EFG Asset Management North America Corp.Bought 128 shares on 7/26/2024Ownership: 0.054%Legato Capital Management LLCSold 5,072 shares on 7/26/2024Ownership: 0.009%Louisiana State Employees Retirement SystemBought 1,100 shares on 7/24/2024Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions GKOS Stock Analysis - Frequently Asked Questions How have GKOS shares performed this year? Glaukos' stock was trading at $79.49 at the beginning of the year. Since then, GKOS shares have increased by 50.7% and is now trading at $119.82. View the best growth stocks for 2024 here. How were Glaukos' earnings last quarter? Glaukos Co. (NYSE:GKOS) announced its quarterly earnings data on Wednesday, May, 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.12. Glaukos's revenue for the quarter was up 15.8% on a year-over-year basis. What is Thomas W. Burns' approval rating as Glaukos' CEO? 10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Glaukos IPO? Glaukos (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. Who are Glaukos' major shareholders? Top institutional investors of Glaukos include Bank of New York Mellon Corp (0.82%), Allspring Global Investments Holdings LLC (0.82%), Assenagon Asset Management S.A. (0.11%) and EFG Asset Management North America Corp. (0.05%). Insiders that own company stock include Joseph E Gilliam, Thomas William Burns, Alex R Thurman, Marc Stapley and Gilbert H Kliman. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA) and Teladoc Health (TDOC). This page (NYSE:GKOS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Glaukos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
